Standard
Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management : a prospective observational study. / Bytzer, Peter; Pratt, Stephen; Elkin, Eric; Næsdal, Jørgen; Sörstadius, Elisabeth.
In:
American Journal of Cardiovascular Drugs, Vol. 13, No. 1, 02.2013, p. 27-35.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Bytzer, P, Pratt, S, Elkin, E, Næsdal, J & Sörstadius, E 2013, '
Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study',
American Journal of Cardiovascular Drugs, vol. 13, no. 1, pp. 27-35.
https://doi.org/10.1007/s40256-012-0001-4
APA
Bytzer, P., Pratt, S., Elkin, E., Næsdal, J., & Sörstadius, E. (2013).
Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study.
American Journal of Cardiovascular Drugs,
13(1), 27-35.
https://doi.org/10.1007/s40256-012-0001-4
Vancouver
Bytzer P, Pratt S, Elkin E, Næsdal J, Sörstadius E.
Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study.
American Journal of Cardiovascular Drugs. 2013 Feb;13(1):27-35.
https://doi.org/10.1007/s40256-012-0001-4
Author
Bytzer, Peter ; Pratt, Stephen ; Elkin, Eric ; Næsdal, Jørgen ; Sörstadius, Elisabeth. / Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management : a prospective observational study. In: American Journal of Cardiovascular Drugs. 2013 ; Vol. 13, No. 1. pp. 27-35.
Bibtex
@article{f4575825a667471ba073897db75265d7,
title = "Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study",
abstract = "Continuous low-dose acetylsalicylic acid (aspirin; ASA) is a mainstay of cardiovascular (CV) risk management. It is well established, however, that troublesome upper gastrointestinal (GI) symptoms are commonly experienced among low-dose ASA users.",
author = "Peter Bytzer and Stephen Pratt and Eric Elkin and J{\o}rgen N{\ae}sdal and Elisabeth S{\"o}rstadius",
year = "2013",
month = feb,
doi = "10.1007/s40256-012-0001-4",
language = "English",
volume = "13",
pages = "27--35",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "1",
}
RIS
TY - JOUR
T1 - Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management
T2 - a prospective observational study
AU - Bytzer, Peter
AU - Pratt, Stephen
AU - Elkin, Eric
AU - Næsdal, Jørgen
AU - Sörstadius, Elisabeth
PY - 2013/2
Y1 - 2013/2
N2 - Continuous low-dose acetylsalicylic acid (aspirin; ASA) is a mainstay of cardiovascular (CV) risk management. It is well established, however, that troublesome upper gastrointestinal (GI) symptoms are commonly experienced among low-dose ASA users.
AB - Continuous low-dose acetylsalicylic acid (aspirin; ASA) is a mainstay of cardiovascular (CV) risk management. It is well established, however, that troublesome upper gastrointestinal (GI) symptoms are commonly experienced among low-dose ASA users.
U2 - 10.1007/s40256-012-0001-4
DO - 10.1007/s40256-012-0001-4
M3 - Journal article
C2 - 23315343
VL - 13
SP - 27
EP - 35
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
SN - 1175-3277
IS - 1
ER -
